Myongji Hospital said Friday that it has signed a business agreement with Helixrus, a biotechnology software company, to accelerate its move toward becoming a biomedical hub hospital.

The two sides will cooperate in joint research and development and technical cooperation in the rapidly growing genome analysis and medicine fields.

Myongji Hospital is a major partner in developing digital healthcare and genome analysis tools promoted by Helixrus, which provides necessary information and advice, including clinical research. Helixrus is currently equipping Myongji Hospital with the infrastructure needed to offer advanced genomic medicine services to patients in the fields of rare diseases, cancer, and liquid biopsy.

“The key to developing biomedical models and future strategies to lead the Fourth Industrial Revolution is a cooperation between medical institutions, which are fundamental in clinical and research fields,” Myongji Hospital Chairman Lee Wang-jun said. “Biotechnology companies that play the role of a platform that can realize them.”

Helixrus CEO Jason Kang also said. “We are happy to build a health platform that can protect the health of patients through cooperation with Myongji Hospital, a representative hospital that is conducting open innovation. We will do our best as a partner to create synergy for a healthy future society.”

The hospital expects to create a successful real case of open innovation that utilizes the characteristics and strengths of each other, Lee added.